Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 17/20 | 0.67 |
| ▸ | GABRP | O00591 | 1/20 | 0.57 |
| ▸ | GABRD | O14764 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.57 |
| ▸ | GABRE | P78334 | 1/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.57 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.57 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.57 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.56 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158601 | 1.00 | HCAR3 (0.67) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Ammonia Solution, Strong SCHEMBL28249483 | 0.98 | HCAR3 (0.65) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL5789616 | 0.98 | HCAR3 (0.65) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Acetone SCHEMBL7024428 | 0.94 | HCAR3 (0.66) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Succinic Acid SCHEMBL23070477 | 0.91 | HCAR3 (0.57) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Succinimide SCHEMBL28163974 | 0.87 | HCAR3 (0.53) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Succinimide SCHEMBL25397856 | 0.86 | HCAR3 (0.51) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| Benzaldehyde SCHEMBL27567924 | 0.86 | HCAR3 (0.55) | HCAR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8722229 | 0.84 | NNMT (0.50) | HCAR3HCAR2 | |
| SCHEMBL383413 | 0.84 | NNMT (0.70) | HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2024-09-12 | — | — | US | claimed |
| EP-4412996-A1 | RADIOLABELLED FIBROBLAST ACTIVATION PROTEIN LIGANDS | Philochem AG (CH) | 2024-08-14 | — | — | EP | claimed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | claimed |
| US-11896683-B2 | Radiolabelled material for targeted administration | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2024-02-13 | — | — | US | claimed |
| WO-2023057457-A1 | RADIOLABELLED FIBROBLAST ACTIVATION PROTEIN LIGANDS | PHILOCHEM AG (CH) | 2023-04-13 | — | — | WO | claimed |
| CN-110290816-B | Radiolabelled materials for targeted administration | 澳大利亚国立大学 | 2022-09-30 | — | — | CN | claimed |
| US-12636386-B2 | Compositions and methods for the treatment and imaging of cancer | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3634474-B1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL EUROPE GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12569576-B2 | Compositions and methods for measuring oxidative stress | WASHINGTON UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | disclosed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | disclosed |
| WO-2022152701-A1 | COMBINATION THERAPY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152656-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022150443-A1 | FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS, AND DELIVERY TO THE CENTRAL NERVOUS SYSTEM | PURDUE RESEARCH FOUNDATION (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3997130-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. Hoffmann-La Roche AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3993839-A1 | RADIOPHARMACEUTICAL COMPOUND AND COMPOSITION FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF INTERLEUKIN-2 RECEPTOR POSITIVE CELLS, PROCESS FOR THE PREPARATION THEREOF, RELATED KIT AND USES THEREOF | Sapienza Universita di Roma (IT) | 2022-05-11 | — | — | EP | disclosed |
| CN-114341188-A | Antibodies that bind to cancer cells and target radionuclides to said cells | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022058308-A1 | METHOD AND KIT FOR DETECTING TOXINS AND PATHOGENS BY LIGAND BINDING ASSAYS USING DEFORMABLE COLLODIAL PARTICLES | Technische Universität Dresden (DE) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569576-B2 | Compositions and methods for measuring oxidative stress | MPO, LPO, GPX1 | HCAR3 3787/4885GABRP 3800/4885GABRD 4705/4885 |
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | HCAR3 129/4885GABRP 1065/4885GABRD 1588/4885 |
| US-11896683-B2 | Radiolabelled material for targeted administration | MPI, PBRM1, PCNA | HCAR3 1686/4885GABRP 2834/4885GABRD 4474/4885 |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | HCAR3 129/4885GABRP 1065/4885GABRD 1588/4885 |
| US-12636386-B2 | Compositions and methods for the treatment and imaging of cancer | GBA1, GALC, CD47 | HCAR3 2501/4885GABRP 2669/4885GABRD 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.